Third time the charm for Alzheimer's drug?

Share this article:

Eli Lilly's experimental Alzheimer's treatment was ruled a failure in two earlier trials. But when investigators combined solanezumab's data from both tests, they discovered that cognitive declines were slowed by 34% among patients who started out with mild symptoms. Based on those results, solanezumab has been selected for a federally sponsored study for people who have not yet suffered significant memory loss. Brigham and Women's Hospital is helping coordinate the three-year investigation, which could cost up to $100 million."This is the first time investigators will test an amyloid-clearing drug in older individuals thought to be in the pre-symptomatic stage of Alzheimer's disease," the hospital announced. They are hoping the medication will reduce memory decline by 30%.

Share this article:

More in Products

FDA approves weight management drug

The U.S. Food and Drug Administration has approved Contrave as a treatment for chronic weight management. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation.

PDI introduces new swab

PDI introduces new swab

PDI has debuted the PrevanticsĀ® Device Swab, a chlorhexidine gluconate/alcohol solution that has received market authorization from the U.S. Food and Drug Administration for disinfecting needleless access sites prior to ...

Oregon Freeze Dry releases Easy Meal

Oregon Freeze Dry releases Easy Meal

A new brand from Oregon Freeze Dry is designed to help long-term care and other healthcare facilities prepare for a disaster.